Skip to contentpdufa.bio
Home › Decisions › TEVA 2026-11-16

TEVA FDA decision: Nov 13, 2026 (announced Nov 16)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET
✓ APPROVED

IGALMI (dexmedetomidine sublingual film) was approved by the FDA for at-home agitation in bipolar disorder or schizophrenia (sNDA); the approval was announced on November 16, 2026.

Verified against: FDA action day November 13, 2026 (NDA 215390 S-003) · Announcement November 16, 2026 (Teva press release) · Goal date November 14, 2026 (BioXcel Therapeutics, Inc. 8-K).

This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 1:24 AM ET (public commit ce46f16). Dates on this page are the FDA's and the sponsor's; this line is ours.

Teva announced on November 16, 2026 that the FDA approved IGALMI (dexmedetomidine) sublingual film for at-home use, the first at-home treatment for agitation associated with schizophrenia, schizoaffective disorder or bipolar I or II disorder in adults.

Run-up into the decision (T-120 → T+0)

announced 11/16/26$44.5$30.155/27/26announced 11/16/26$44.5$30.155/27/26
Daily close, T-120 (5/27/26) through T+0. Run-up high $44.5 on 11/13/26, low $30.15 on 7/22/26 (T-120 to T-1). Announced 11/16/26 (FDA action 11/13/26). Historical price action, not a forecast.

Key facts

FDA decision date2026-11-13
Announced2026-11-16
OutcomeApproved
Drug / candidateIGALMI (dexmedetomidine) at-home sNDA
IndicationAcute agitation with schizophrenia, schizoaffective disorder or bipolar I/II disorder: at-home use (adults)
CompanyTeva Pharmaceutical Industries
Market-cap tierLarge
120-day run-up (T-120→T-1)+28.6%
Decision-day move-4.3%
Move measured on2026-11-16 close (the announcement day), against the 2026-11-13 close
Cohort decision-day move (history)1.0% median (n=828)

The PDUFA goal date was November 14, 2026 (a Saturday; BioXcel 8-K, May 15, 2026). The FDA's own record dates the action November 13, 2026, 1 day before the goal date; Teva announced it on November 16, 2026.

Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.

Primary source: Teva press release, November 16, 2026

FDA record of the action: the FDA approved on November 13, 2026, per NDA 215390 S-003 (Drugs@FDA). The sponsor announced it on November 16, 2026. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.

Questions

Was IGALMI (dexmedetomidine) at-home sNDA approved by the FDA?

Yes. The FDA approved the application for IGALMI (dexmedetomidine) at-home sNDA on November 13, 2026, per the FDA's own record. The company announced it on November 16, 2026. The primary source is linked on this page.

Which company is behind IGALMI (dexmedetomidine) at-home sNDA?

IGALMI (dexmedetomidine) at-home sNDA is a Teva Pharmaceutical Industries (TEVA) program. The FDA decision came on November 13, 2026; the company's own announcement is linked on this page.

How did TEVA stock react to the FDA decision?

TEVA moved -4.3%, measured as the 2026-11-16 close (the announcement day) against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.